Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEONARDA-2: Lerociclib + Letrozole in 1st-line HR+/HER2- Breast Cancer
NCT05851014Phase 3Recruiting
- Sponsor
- Genor Biopharma
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lerociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Genor Biopharma. Started Jan 2022; status: recruiting.
02
Drugs
lerociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05851014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851014.